Market Closed -
Japan Exchange
02:00:00 2024-05-31 EDT
5-day change
1st Jan Change
1,987
JPY
+1.95%
+1.74%
-1.49%
Zeria Pharmaceutical Co., Ltd. Announces Earnings Guidance for the Year Ending March 31, 2022
November 04, 2021 at 03:00 am
Zeria Pharmaceutical Co., Ltd. announced earnings guidance for the year ending March 31, 2022. FOr the year, the company expected Net sales to be JPY 60,000 Million, Operating profit to be JPY 5,300 Million, Profit attributable to
owners of parent to be JPY 3,700 Million and Basic earnings per share to be JPY 81.80.
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2024, Payable on June 28, 2024
05-09
CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2025
05-09
CI
Zeria Pharmaceutical Co., Ltd. Provides Second Quarter and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2025
05-09
CI
Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints
04-23
CI
Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3
02-16
MT
Japanese Shares End Firmer on Friday on BoJ Policy Outlook
11-17
MT
Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal
11-16
MT
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of Fiscal Year Ending March 31, 2024, Payable on December 1, 2023
11-15
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
11-15
CI
Zeria Pharmaceutical’s Attributable Profit Up 12.1% in Fiscal Q1 on Absence of Forex Losses
23-08-22
MT
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024
23-08-21
CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024
23-08-21
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Second Quarter of 2024
23-08-21
CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.
23-05-16
CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 263,900 shares, representing 0.6% for ¥545.29 million.
23-05-11
CI
Zeria Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2024
23-05-11
CI
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024
23-05-11
CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2024
23-05-11
CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.
23-04-04
CI
Zeria Pharmaceutical's Attributable Profit Soars 48% in Fiscal Nine Months
23-02-21
MT
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
23-02-02
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
23-02-02
CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.
23-01-06
CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
22-11-02
CI
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of the Year Ending March 31, 2023, Payable on December 1, 2022
22-11-02
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
More about the company
Last Close Price
1,987
JPY
Average target price
2,810
JPY
Spread / Average Target
+41.42%
Consensus
1st Jan change
Capi.
-1.49% 557M +15.91% 41.97B +22.40% 22.34B +18.48% 15.25B +16.12% 14B +45.12% 12.06B -9.58% 6.8B -0.05% 6.79B -8.87% 5.73B +14.18% 5.49B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ZERIA PHARMACEUTICAL CO., LTD. 
